Factors Influencing Medication Adherence to Oral Anticancer Drugs

Yeon Hee Lee; Ihn Sook Jeong

doi:10.5388/aon.2013.13.4.201

Journal List > Asian Oncol Nurs > v.13(4) > 1081776

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee and Jeong: Factors Influencing Medication Adherence to Oral Anticancer Drugs

Original Article

Asian Oncology Nursing 2013; 13(4): 201-209.

Published online: 31 December 2013

DOI: https://doi.org/10.5388/aon.2013.13.4.201

Factors Influencing Medication Adherence to Oral Anticancer Drugs

Yeon Hee Lee, Ihn Sook Jeong

College of Nursing, Pusan National University, Yangsan, Korea.

Address reprint requests to: Lee, Yeon Hee. College of Nursing, Pusan National University, Yangsan 626-870, Korea. Tel: +82-51-510-8318, Fax: +82-51-510-8308, vandi@pusan.ac.kr

Received 15 October 2013 Accepted 10 December 2013

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

The purpose of this study was to identify factors that influence on medication adherence to oral anticancer drugs.

Methods

147 cancer patients receiving oral anticancer drugs were surveyed. The survey content included medication adherence, social support, depression, self-efficacy and symptom experience.

Results

The mean medication adherence was 6.77 based on 8 points (84.6 based on 100 points). The influencing factors on medication adherence were symptom experience (β=-.19), decision of oral chemotherapy (β=.25) and social support (β=.21), and 17.0% of the variance in medication adherence was explained by these three factors in stepwise multiple regression analysis.

Conclusion

The level of medication adherence to oral anticancer drugs was relatively high, and increased by decreasing symptom experience, and increasing social support. Considering the medication adherence is related with positive treatment outcome, nursing effort to improve medication adherence by decreasing symptom experience, and increasing social support is needed.

Keywords: Mouth, Drug Therapy, Medication Adherence, Neoplasms

Figures and Tables

Table 1

Level of Medication Adherence to Oral Chemotherapy (N=147)

Table 2

Medication Adherence by Socio-demographic and Disease-related Characteristics (N=147)

ECOG PS=Eastern Cooperative Oncology Group Performance Scale.

Table 3

Medication Adherence by Characteristics of Oral Chemotherapy (N=147)

IV=Intravenous.

^*Multiple comparison by Scheffé' test.

Table 4

Correlation between Variables (N=147)

Table 5

Influencing Factors on Medication Adherence by Stepwise Multiple Regression (N=145)

References

1. Banna GL, Collovà E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, et al. Anticancer oral therapy: Emerging related issues. Cancer Treat Rev. 2010; 36(8):595–605.

2. Regnier Denois V, Poirson J, Nourissat A, Jacquin JP, Guastalla JP, Chauvin F. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care (Engl). 2011; 20(4):520–527.

3. Benjamin L, Cotté FE, Philippe C, Mercier F, Bachelot T, Vidal-Trécan G. Physicians' preferences for prescribing oral and intravenous anticancer drugs: a Discrete Choice Experiment. Eur J Cancer. 2012; 48(6):912–920.

4. Hartigan K. Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs. 2003; 7:6 Suppl. 21–24.

5. Moore S. Facilitating oral chemotherapy treatment and compliance through patient/family-focused education. Cancer Nurs. 2007; 30(2):112–122.

6. Foulon V, Schoffski P, Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg. 2011; 66(2):85–96.

7. World Health Organization. Adherence to long-term therapies: evidence for actions. Geneva: WHO;Accessed April 15, 2013. Available from: http://www.who.int/chp/knowlege/publications/adherence_report/en/print.html.

8. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009; 59(1):56–66.

9. Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev. 2013; 39(6):610–621.

10. Gater A, Heron L, Abetz-Webb L, Cooms J, Simmons J, Guilhot F, et al. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res. 2012; 36:817–825.

11. Marques PAC, Pierin AMG. Factors that affect cancer patient compliance to oral anti-neoplastic therapy. Acta Paul Enferm. 2008; 21(2):323–329.

12. Banning M. Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care (Engl). 2012; 21(1):10–19.

13. Jabbour EJ, Kantarjian H, Eliasson L, Megan Cornelison A, Marin D. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012; 87(7):687–691.

14. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002; 94(9):652–661.

15. Choi JS. Adherence to oral anticancer drugs in elderly cancer patients [dissertation]. Seoul: Seoul National Univ.;2011.

16. Lee ER. Patient compliance with oral anticancer drug medication and factors affecting compliance with medication [dissertation]. Seoul: Seoul National Univ.;2006.

17. Kim JH. Influencing factors on medication adherence in colorectal cancer patient receiving oral chemotherapy. Asian Oncol Nurs. 2012; 12(3):213–220.

18. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New York: Academic Press;1977.

19. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory. Cancer. 2000; 89(7):1634–1646.

20. Yun YH, Mendoza TR, Kang IO, You CH, Roh JW, Lee CG, et al. Validation study of the Korean version of the M. D. Anderson Symptom Inventory. J Pain Symptom Manage. 2006; 31(4):345–352.

21. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977; 1(3):385–401.

22. Cho MJ, Kim KH. Diagnostic validity of the CES-D (Korean Version) in the assessment of DSM-III-R Major Depression. J Korean Neuropsychiatr Assoc. 1993; 32(3):381–399.

23. Heitzmann CA, Merluzzi TV, Jean-Pierre P, Roscoe JA, Kirsh KL, Passik SD. Assessing self-efficacy for coping with cancer: development and psychometric analysis of the brief version of the Cancer Behavior Inventory (CBI-B). Psychooncology. 2011; 20(3):302–312.

24. Zimet GD, Dahlem NW, Zimet SG, Farley GK. The multidimensional scale of perceived social support. J Pers Assess. 1988; 52(1):30–41.

25. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008; 10(5):348–354.

26. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005; 59(1):97–102.

27. Kirk MC, Hudis CA. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer. 2008; 8(2):155–161.

28. Lien CY, Lin HR, Kuo IT, Chen ML. Perceived uncertainty, social support and psychological adjustment in older patients with cancer being treated with surgery. J Clin Nurs. 2009; 18(16):2311–2319.

29. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med. 2000; 160(14):2101–2107.

30. Darkow T, Henk HJ, Thomas SK, Weiwei F, Baladi JF, Goldberg GA, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007; 25(6):481–496.

TOOLS

Similar articles